{
    "clinical_study": {
        "@rank": "109138", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo capsules three times daily"
            }, 
            {
                "arm_group_label": "EPI-743 400 mg", 
                "arm_group_type": "Active Comparator", 
                "description": "EPI-743 at a dose of 400 mg three times daily"
            }, 
            {
                "arm_group_label": "EPI-743 200 mg", 
                "arm_group_type": "Active Comparator", 
                "description": "EPI-743 at a dose of 200 mg three times daily"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to examine the effects of EPI-743 on visual function and\n      neurologic function in patients with Friedreich's ataxia."
        }, 
        "brief_title": "Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Friedreich's Ataxia", 
        "condition_browse": {
            "mesh_term": [
                "Ataxia", 
                "Friedreich Ataxia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Diagnosis of genetically confirmed Friedreich's ataxia\n\n          2. Visual acuity at baseline more than 15 letters on EDTRS at four meters\n\n          3. FARS score of 20 to 90\n\n          4. Agreement to use contraception if within reproductive years (see specifics in section\n             D1, page 21)\n\n          5. Hormone replacement therapy, if used, must remain stable for the duration of the\n             study\n\n          6. Willingness and ability to comply with study procedures\n\n          7. Willingness and ability to arrive at study site day prior to evaluations\n\n          8. Abstention from use of dietary supplements and non-prescribed medications at least 30\n             days prior to initiation of treatment and for the duration of the study. This would\n             specifically include idebenone, Coenzyme Q10 and vitamin E\n\n          9. Abstention from use of other investigative or non-approved drugs within 30 days of\n             enrollment and for the duration of the study\n\n        Exclusion Criteria:\n\n          1. Allergy to EPI-743 or sesame oil or nuts\n\n          2. Clinically significant bleeding condition or abnormal PT/PTT INR (INR > two; PTT >\n             two-times normal)\n\n          3. Liver insufficiency with LFTs greater than three-times upper normal limit at\n             screening\n\n          4. Renal insufficiency with creatinine > 1.5 at screening\n\n          5. Fat malabsorption syndromes\n\n          6. Any other respiratory chain diseases of the mitochondria or inborn errors of\n             metabolism\n\n          7. Any other ophthalmologic conditions\n\n          8. History of alcohol or drug abuse\n\n          9. Clinically significant cardiomyopathy with ejection fraction < 40 percent at\n             screening\n\n         10. Clinically significant arrhythmia within past two years requiring treatment\n\n         11. Anticoagulant therapy within 30 days of enrollment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01728064", 
            "org_study_id": "EPI2010-006"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo capsules", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "EPI-743 400 mg", 
                "intervention_name": "EPI-743 400 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "EPI-743 200 mg", 
                "intervention_name": "EPI-743 200 mg", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Friedreich's", 
            "Ataxia", 
            "FRDA", 
            "FA", 
            "EPI-743", 
            "Edison"
        ], 
        "lastchanged_date": "December 4, 2013", 
        "link": {
            "description": "Edison Pharmaceuticals Web Site", 
            "url": "http://edisonpharma.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "University of California Los Angeles"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "University of South Florida"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "Childrens Hospital of Philadelphia"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Safety and Efficacy Study of EPI-743 on Visual Function in Patients With Friedreich's Ataxia", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Low contrast visual acuity", 
            "measure": "Visual Function", 
            "safety_issue": "No"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01728064"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Roth 28 hue test", 
                "measure": "Color vision", 
                "safety_issue": "No"
            }, 
            {
                "description": "Friedreich's ataxia rating scale", 
                "measure": "Neurologic function"
            }, 
            {
                "description": "25-foot walk test", 
                "measure": "Neuromuscular function", 
                "safety_issue": "No"
            }, 
            {
                "description": "9-hole peg test", 
                "measure": "Neuromuscular function", 
                "safety_issue": "No"
            }, 
            {
                "description": "SF-36", 
                "measure": "Quality of life", 
                "safety_issue": "No"
            }, 
            {
                "description": "Blood biomarker levels", 
                "measure": "Disease biomarkers"
            }, 
            {
                "description": "Echocardiogram", 
                "measure": "Cardiac function", 
                "safety_issue": "No"
            }, 
            {
                "description": "Number of adverse events", 
                "measure": "Safety", 
                "safety_issue": "Yes"
            }, 
            {
                "description": "Patient Global Improvement Scale", 
                "measure": "Disease improvement"
            }, 
            {
                "description": "Visual field exam", 
                "measure": "Visual Function", 
                "time_frame": "Baseline, Months 3, 6, 9 and 12"
            }
        ], 
        "source": "Edison Pharmaceuticals Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Edison Pharmaceuticals Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}